What drove the ALTHX.PA stock spike today?

The ALTHX.PA stock spike was driven by unusually high volume of **861,345** shares and market interest in Theranexus' clinical pipeline; small-cap biotech often moves sharply on trial updates or investor speculation.

What is Meyka AI's short-term forecast for ALTHX.PA stock?

Meyka AI's forecast model projects a one-year price of **€3.66** for ALTHX.PA stock, which implies about **-12.06%** from the current **€4.16**; this is a model projection, not a guarantee.

Is ALTHX.PA stock a buy after the after-hours move?

After a large volume spike, ALTHX.PA stock requires news confirmation and risk controls; Meyka AI grades it **B (HOLD)**, so traders should wait for follow-through and investors should assess funding and clinical milestones first.

Where can I find official updates on ALTHX.PA stock?

Official updates are on Theranexus' corporate site and regulatory filings; use the company's investor page and reputable market pages like Reuters for confirmations before trading ALTHX.PA stock.

EU Stocks

ALTHX.PA Theranexus (EURONEXT) rises 32.06% on heavy volume 13 Feb 2026: monitor follow-through

ByHuzaifa Zahoor February 13, 2026February 13, 2026

The ALTHX.PA stock jumped 32.06% after hours to €4.16 on 13 Feb 2026, led by an unusually high 861,345 share volume versus a 124,662 average. This sharp move marks ALTHX.PA stock as a high-volume mover on EURONEXT in the Europe healthcare sector. Traders should note the gap from the 50-day average €2.14 and the 200-day average €1.88, and we use Meyka AI-powered market analysis platform data to explain the trade and next checkpoints.